MXCT
NASDAQMaxCyte Inc.
Price$1.30+0.01 (+0.39%)
01:30 PM07:00 PM
News · 26 weeks26+200%
2026-04-192026-10-11
Mix990d
- Other3(33%)
- SEC Filings3(33%)
- Earnings2(22%)
- Leadership1(11%)
Latest news
25 items- SECSEC Form 8-K filed by MaxCyte Inc.8-K - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance. Preliminary Third Quarter Revenue Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025.Strategic Platform License (SPL) Program-related revenue of more than $1.0 million, including milestone revenue of $1.0 million received in the thi
- PRMaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development OfficerROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the world. He knows firsthand what it takes to translate strategy into growth," said Maher Masoud, President and Chief Executive Officer. "I am confident that Sidharth’s expertise will support MaxCyte’
- PRMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricted stock unit ("RSU") award with respect to 110,000 shares of MaxCyte’s common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporat
- PRMaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapiesROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte’s SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs). SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify ove
- SECSEC Form 10-Q filed by MaxCyte Inc.10-Q - MAXCYTE, INC. (0001287098) (Filer)
- SECMaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte Reports Second Quarter 2026 Financial ResultsReports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 GuidanceRepurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the BoardFollowing end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation ce
- PRMaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy DevelopmentROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs. The license provides Genentech with access to MaxCyte’s ExPERT GTx® platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to su
- PRMaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live a
- INSIDERDirector Johnston John Joseph was granted 30,421 shares, increasing direct ownership by 18% to 201,581 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Hemrajani Rekha was granted 30,421 shares, increasing direct ownership by 76% to 70,314 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Erck Stanley C was granted 30,421 shares, increasing direct ownership by 8% to 428,749 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Douglas Richard was granted 30,421 shares, increasing direct ownership by 13% to 260,998 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Collins Cynthia was granted 30,421 shares, increasing direct ownership by 38% to 111,310 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Brooke William W was granted 30,421 shares, increasing direct ownership by 20% to 181,300 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Balthrop Patrick J was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Al-Wakeel Yasir B. was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- SECMaxCyte Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form 8-K filed by MaxCyte Inc.8-K - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form 10-Q filed by MaxCyte Inc.10-Q - MAXCYTE, INC. (0001287098) (Filer)
- SECMaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 GuidanceFirst quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results an
- SECSEC Form DEFA14A filed by MaxCyte Inc.DEFA14A - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form DEF 14A filed by MaxCyte Inc.DEF 14A - MAXCYTE, INC. (0001287098) (Filer)
MXCT FAQ
7 questionsWhat does MaxCyte Inc. do?
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and...Where does MXCT stock trade?
MaxCyte Inc. (MXCT) is listed on NASDAQ.What sector and industry is MXCT in?
MaxCyte Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did MaxCyte Inc. go public?
MaxCyte Inc. (MXCT) completed its IPO in 2021.What are analysts saying about MXCT?
MaxCyte Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-08-11.What companies are similar to MXCT?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), MEDP (Medpace Holdings Inc.), PPD (PPD, Inc.), CRL (Charles River Laboratories International Inc.). Compare MXCT side-by-side with any of them on Quantisnow.How can I track MXCT on Quantisnow?
Quantisnow aggregates MaxCyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MXCT to receive live email and push alerts on every new disclosure.